What is Jagsonpal Pharmaceuticals Ltd's PE ratio?

Jagsonpal Pharmaceuticals Ltd trades at a P/E ratio of 32.00.

What is Jagsonpal Pharmaceuticals Ltd's market cap?

Jagsonpal Pharmaceuticals Ltd's market capitalisation is ₹1,507 Cr.

When did Jagsonpal Pharmaceuticals Ltd last report results?

Jagsonpal Pharmaceuticals Ltd last reported Q2FY27 results on 28 Oct '26.

What is Jagsonpal Pharmaceuticals Ltd's ROE?

Jagsonpal Pharmaceuticals Ltd's return on equity (ROE) is 17.3%.

What sector is Jagsonpal Pharmaceuticals Ltd in?

Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)

₹216.09

Mkt cap

₹1,507 Cr

P/E ratio

32.00

P/B

5.24

Div yield

1.75%

ROE

17.30%

ROCE

22.70%

EPS (TTM)

₹6.75

Book value

₹41

52W range

155–265

Sector

Healthcare

Price history

Previous close

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients [1]

NSE JAGSNPHARMBSE 507789

Health check

Constructive

ValuationFair

ProfitabilityStrong

GrowthModerate

TechnicalsNeutral

52-week range

−18.30% from high

₹216

₹155+39.41% from low₹265

Current

₹216.09

Prev close

₹221.94

Day

−2.64%

Price performance

−3.13%

+1.53%

−8.40%

−8.91%

+2.95%

−1.54%

YTD

+11.31%

Financials

Revenue, profit & margin

P/E ratio

32.0×

JAGSNPHARM is 7% below the sector median of 34.6×

JAGSNPHARM32.0×

Sector median34.6×

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026NSE
Sales	60	58	47	43	61	75	74	59	76	74	73	64	82	81
Expenses	52	49	44	41	51	58	58	50	61	58	57	53	65	65
Operating Profit	9	8	3	3	10	16	16	9	14	16	16	11	17	17
OPM %	14%	14%	7%	6%	17%	22%	21%	15%	19%	22%	22%	17%	21%	21%
Other Income	2	2	3	2	-2	2	26	3	3	3	1	3	3	2
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	1	2	2	2	2	2	2	2	2	2
Profit before tax	10	10	5	5	7	15	39	9	14	17	15	12	18	17
Tax %	26%	25%	25%	22%	25%	25%	17%	24%	25%	25%	25%	25%	25%	25%
Net Profit	7	7	4	4	5	11	32	7	11	13	11	9	13	13
EPS in Rs	1.14	1.14	0.60	0.54	0.81	1.73	4.82	0.99	1.62	1.89	1.64	1.31	2.00	1.91
Raw PDF														—

Earnings

Results dates & reactions

No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move −0.75% · closed higher next day 1 of last 2

	Q1FY27	Q2FY27
Broadcast	29 Jul '26◦	28 Oct '26◦
Earnings day	+2.40%	−3.91%
+1 day	+0.13%	−6.91%
+5 days	+3.28%	—
+15 days	+1.08%	—
+30 days	+1.08%	—
Filing	XBRL	XBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Jun 2026

69.06%Promoter

Promoters69.06%1.17

FIIs2.30%0.14

DIIs0.62%0.40

Public28.04%1.40

Ownership trend

Peers

8 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
Sun Pharma.Inds.	₹1,837.30	34.90	4,40,830	0.87%	2,901	+5.95%	15,300	+10.46%	20.53%
Divi's Lab.	₹9,375.00	83.54	2,48,877	0.32%	902	+65.50%	3,080	+27.80%	21.97%
Torrent Pharma.	₹4,840.00	82.51	1,84,098	0.79%	566	+5.79%	4,921	+54.85%	15.19%
Zydus Lifesci.	₹1,160.00	23.77	1,15,710	0.09%	990	−35.09%	8,017	+21.96%	21.14%
Cipla	₹1,394.50	31.48	1,12,656	0.93%	786	−39.19%	7,119	+2.33%	15.49%
Laurus Labs	₹1,954.00	96.56	1,05,577	0.10%	362	+125.49%	2,026	+29.10%	17.76%
Aurobindo Pharma	₹1,734.00	26.39	99,771	0.23%	1,032	+28.11%	9,150	+16.30%	12.86%
Jagsonpal Pharma	₹228.42	32.05	1,507	1.75%	13	+22.13%	82	+8.76%	22.73%
Median: 158 Co.	₹433.90	34.56	2,205	0.08%	13	+29.57%	164	+18.57%	14.96%

Filings

Annual reports15

Annual Report 2026 Annual Report 2025 Annual Report 2024 Annual Report 2023 Annual Report 2022 Annual Report 2021 Annual Report 2020 Annual Report 2019 Annual Report 2018 Annual Report 2017 Annual Report 2016 Annual Report 2015 Annual Report 2014 Annual Report 2013 Annual Report 2012

Credit ratings6

Rating update 22 Jan 2025icra Rating update 21 Jun 2024icra Rating update 14 Apr 2023icra Rating update 10 Oct 2022icra Rating update 10 Mar 2022icra Rating update 4 Mar 2021icra

Announcements5

Shareholder Meeting / Postal Ballot-Outcome of AGM 18 Sep - 47th AGM held on September 18, 2026; FY26 accounts, dividend, director appointments approved.Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Aug - Newspaper Publication for dispatch of Notice of 47th Annual General Meeting, Annual Report 2025-26 and e-voting Notice Of 47Th Annual General Meeting And Annual Report For The FY 2025-26 27 Aug - 47th AGM on September 18, 2026; dividend record date September 4, 2026; FY26 annual report issued.Business Responsibility and Sustainability Reporting (BRSR) 27 Aug - Jagsonpal Pharmaceuticals filed its BRSR for FY 2025-26.Reg. 34 (1) Annual Report. 27 Aug - 47th AGM on September 18, 2026; annual report issued; dividend record date September 4, 2026.